NASDAQ:CNTX Context Therapeutics (CNTX) Stock Price, News & Analysis $2.32 +0.04 (+1.75%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.21▼$2.3850-Day Range$1.79▼$2.6652-Week Range$0.77▼$2.75Volume96,310 shsAverage Volume306,844 shsMarket Capitalization$174.00 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Context Therapeutics alerts: Email Address Context Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside158.6% Upside$6.00 Price TargetShort InterestHealthy3.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.28 out of 5 starsMedical Sector466th out of 910 stocksPharmaceutical Preparations Industry218th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingContext Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageContext Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Context Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.13% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Context Therapeutics has recently decreased by 7.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTX. Previous Next 3.3 News and Social Media Coverage News SentimentContext Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Context Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.30% of the stock of Context Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.03% of the stock of Context Therapeutics is held by institutions.Read more about Context Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Context Therapeutics are expected to remain at ($0.31) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Context Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Context Therapeutics Stock (NASDAQ:CNTX)Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Read More CNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTX Stock News HeadlinesSeptember 6 at 10:25 AM | msn.comContext Therapeutics Strengthens Board with Key AppointmentsSeptember 4 at 7:30 AM | globenewswire.comContext Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of DirectorsSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Context Therapeutics Amid Strong Financials and Promising CLDN6-Targeting TherapiesAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Context Therapeutics as CTIM-76 Shows Promise and Strategic Team Expands Ahead of Clinical TrialsAugust 9, 2024 | finanznachrichten.deContext Therapeutics Inc.: Context Therapeutics Reports Second Quarter 2024 Operating and Financial ResultsAugust 7, 2024 | globenewswire.comContext Therapeutics Reports Second Quarter 2024 Operating and Financial ResultsAugust 6, 2024 | finance.yahoo.comContext Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firmsSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 3, 2024 | msn.comContext Therapeutics Appoints New Chief Medical Officer and VP of Clinical OperationsAugust 1, 2024 | globenewswire.comContext Therapeutics Appoints Chief Medical Officer and Vice President of Clinical OperationsJuly 10, 2024 | globenewswire.comContext Therapeutics Acquires Phase 1-ready T cell Engager CT-95May 22, 2024 | investorplace.comThe 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit GainsMay 16, 2024 | msn.comPiper Sandler Initiates Coverage of Context Therapeutics (CNTX) with Overweight RecommendationMay 16, 2024 | markets.businessinsider.comOptimistic Outlook for Context Therapeutics’ CTIM-76 Based on Targeting Efficacy and Market PotentialMay 11, 2024 | msn.comContext Therapeutics Posts Strong Q1 Financials, Advances Key Cancer Drug TrialsMay 9, 2024 | investorplace.comCNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024May 8, 2024 | globenewswire.comContext Therapeutics Reports First Quarter 2024 Operating and Financial ResultsSee More Headlines Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTX CUSIPN/A CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$10.00 Low Stock Price Target$4.50 Potential Upside/Downside+158.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.13% Return on Assets-48.60% Debt Debt-to-Equity RatioN/A Current Ratio64.03 Quick Ratio64.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book1.72Miscellaneous Outstanding Shares74,998,000Free Float65,773,000Market Cap$174.00 million OptionableNot Optionable Beta2.31 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Martin A. Lehr (Age 40)Co-Founder, President, CEO & Director Comp: $674.08kMs. Jennifer Minai-Azary (Age 46)CFO & Treasurer Comp: $504.14kMr. Alex C. Levit Esq. (Age 45)Chief Legal Officer & Corporate Secretary Comp: $483.83kMr. Christopher Beck M.B.A.Senior Vice President of OperationsKey CompetitorsUnicycive TherapeuticsNASDAQ:UNCYMetacrineNASDAQ:MTCRScholar RockNASDAQ:SRRKTravere TherapeuticsNASDAQ:TVTXORIC PharmaceuticalsNASDAQ:ORICView All CompetitorsInstitutional OwnershipNantahala Capital Management LLCBought 1,935,484 shares on 8/20/2024Ownership: 2.581%Driehaus Capital Management LLCBought 2,258,065 shares on 8/16/2024Ownership: 3.011%Blue Owl Capital Holdings LPBought 5,161,290 shares on 8/15/2024Ownership: 6.882%Affinity Asset Advisors LLCBought 1,290,323 shares on 8/15/2024Ownership: 2.159%Ally Bridge Group NY LLCBought 1,160,281 shares on 8/14/2024Ownership: 2.515%View All Institutional Transactions CNTX Stock Analysis - Frequently Asked Questions How have CNTX shares performed this year? Context Therapeutics' stock was trading at $1.13 at the beginning of the year. Since then, CNTX shares have increased by 105.3% and is now trading at $2.32. View the best growth stocks for 2024 here. How were Context Therapeutics' earnings last quarter? Context Therapeutics Inc. (NASDAQ:CNTX) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.04. When did Context Therapeutics IPO? Context Therapeutics (CNTX) raised $25 million in an initial public offering (IPO) on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share. Who are Context Therapeutics' major shareholders? Top institutional investors of Context Therapeutics include Great Point Partners LLC (9.89%), Blue Owl Capital Holdings LP (6.88%), Driehaus Capital Management LLC (3.01%) and Nantahala Capital Management LLC (2.58%). Insiders that own company stock include Martin A Lehr, Jennifer Lynn Minai-Azary and Alex C Levit. View institutional ownership trends. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
